General thoughts on Tildrakizumab

With the availability of tildrakizumab (Ilumya), an interleukin-23 (IL-23) inhibitor, dermatologists are very optimistic about the continued success of this biologic drug used to treat psoriasis patients. More than 50 percent of patients remain clear after 5 years of treatment. Dermatologists report that tildrakizumab has not only given health benefits to those suffering from psoriasis, but also improved their quality of life.

Next Video

Tildrakizumab: the Patient Journey

Long-term use of interleukin-23 (IL-23) psoriasis therapies
This physician-led video initiative explores community experience with the long-term use and effect of interleukin-23 (IL-23) psoriasis therapies.